~/ The results of a second operation for tumor removal in 24 adult patients with supratentorial glioblastoma multiforme or anaplastic astrocytoma were analyzed. The median survival time after reoperation was 14 weeks. Five of the 24 patients lived 6 months or longer after reoperation. Only three of these patients maintained a Karnofsky rating (KR) of at least 60 for 6 months or longer after reoperation.
p
ATIENTS with glioblastoma multiforme rarely enjoy a prolonged survival. The median survival period after conventional treatment by surgical excision and radiotherapy is only 6 to 12 months, m3 Chemotherapy does not greatly prolong life. 11-~a Immunotherapy does not prolong survival of patients receiving surgery, radiotherapy, and chemotherapy? , 5 Although glucocorticoids often lessen neurological symptoms, their use has not been proven to increase longevity.
When tumor recurrence threatens life or impairs neurological function, should a second operation be recommended for tumor removal? Although glioblastoma is the most commonly occurring primary brain tumor, this question has received scant attention in previous studies. We are reporting the effect of a second operation on the duration of survival and the functional abilities in a selected group of patients. We have also analyzed the significance of several factors that were possibly important indicators of likely length of survival after reoperation, including functional capacity just before the second operation, interval between operations, age at second operation, and tumor location.
Clinical Material and Methods

Clinical Material
The study group comprised 24 patients with glioblastoma who underwent two operations for tumor removal at the University of Kentucky (nine patients) and Vanderbilt University (15 patients) and their affiliated Veterans Administration Hospitals between 1966 and 1974 (Table 1) . We have included only adult patients with an interoperative interval of 1 month or longer. Reoperations earlier than 1 month for tumor removal or for infection, hematomas, or shunting were excluded. Only patients with supratentorial glioblas- 1  rt frontal  28, M  70  42  14  56  no  2  rt parieto-occipital  52, M  50  61  11  72  no  3  It temporal  67, M  60  52  10  62  no  4  rt parietal  57, M  30  9  5  14  no  5  rt temporal  52, M  40  16  0  16  no  6  rt frontal  35, M  50  67  25  92  no  7  It frontal  41, M  60  34  27  61  yes  8  rt parietal  48, M  90  117  50  167  yes  9 rt Table 2 .
toma multiforme or anaplastic astrocytoma were included in the study. Patients with low-grade astrocytomas (Grades I and II) at the first operation and glioblastoma at the second operation were excluded, as were patients undergoing more than two operations for tumor removal. The microscopic sections from both institutions were reexamined to confirm the initial diagnosis. Tumor classification was based on the criteria of the National Institutes of Health Brain normal; no complaints; no evidence of disease able to carry on normal activity; minor signs or symptoms normal activity with effort; some signs or symptoms cares for self; unable to carry on normal activity or to do active work requires occasional assistance, but able to care for most needs requires considerable assistance & frequent medical care disabled; requires special care & assistance severely disabled; hospitalization necessary although death not imminent very sick; hospitalization necessary; active supportive treatment necessary moribund; fatal processes progressing rapidly dead Tumor Study Group. 11-13 All nine of the patients from the University of Kentucky received chemotherapy as part of the Brain Tumor Study Group. None of the Vanderbilt patients was given chemotherapy. All of the patients were given a Karnofsky rating (KR) based on the neurological examination prior to reoperation (Table 2) . 4 The KR measures performance status. A score of 60 means that only occasional assistance is required to care for most needs. The patient with a score of 50 requires considerable assistance and frequent medical care.
The general indication for reoperation was recurrent increased intracranial pressure (ICP) and/or focal neurological signs caused by a mass lesion. Uniform criteria were not used to select patients for reoperation. The criterion for performing the second operation was the surgeon's judgment that the patient might benefit from another operation. Reoperated cases accounted for less than 5% of all glioblastoma patients. Cases 4, 15, 16, 18, and 21 had an interval between operations of 3 months or less. Case 4 had reoperation to remove a necrotic cystic neoplasm causing stupor and left hemiplegia. Case 15 had a solid tumor removed which was causing lethargy and increased ICP. Case 16 had lethargy associated with a cystic neoplasm. Case 18 had acute onset of headache and somnolence associated with a recurrent tumor with both cystic and solid components. Case 21 remained obtunded following the first operation. No improvement occurred after radiotherapy. The Table 2 .
second operation was performed to remove recurrent solid tumor.
The median age of the patients was 50.5 years, with a range from 28 to 67 years. There were 16 men and eight women. Eight patients had left hemisphere and 16 had right hemisphere neoplasms. Patients from the two centers were very similar with regard to preoperative KR, age, and interval between operations (Table 3) .
Statistical Method
Comparison of group means was by either a t-test or one-way analysis of variance depending on whether two or more groups were compared. Correlations between age, KR prior to the second operation, and length of survival after reoperation are Pearson product-moment correlation coefficients. A multivariate approach was taken, where we sought to determine the best subset of predictors of survival time after second surgery using both stepwise selection and backward elimination (results for the two approaches agreed). Partial correlation coefficients between age and interval with survival after second surgery adjusted for KR, which was determined to be the only significant predictor of survival through our multivariate analysis, are also reported.
Results
The median survival period after the first operation was 62 weeks and after the second operation was 14 weeks. When the interoperative interval was less than 6 months, median survival after the second operation was only 8.5 weeks. The median survival time was 14.5 weeks when the interval between operations was at least 6 months. When the interoperative interval was at least 12 months, the median survival period after the second operation was 16.5 weeks. Five of the 24 patients lived for 6 months or longer after reoperation. Only three of these patients maintained a KR of at least 60 for 6 months or longer after reoperation.
Karnofsky rating is correlated with survival after reoperation in these 24 patients (p = 0.02, Table 4 ). The interval between first and second operation is significantly related to survival (p = 0.03), but when adjustment is made for the KR the interoperative interval is no longer significantly related to survival after the second operation (p = 0.39, Table 4 ). By multivariant analysis, the patients' age, KR prior to second operation, and interval between operations account for 28% of the variation in survival time after the second operation, with the KR accounting for 24% of the variation. Age considered alone (p = 0.64) or after adjustment for KR (p = 0.58) is not significantly related to survival after the second operation. Sex (p = 0.79) and tumor location (p = 0.32) are not significant predictors of survival after reoperation (Table 5). By reviewing the operative records, we could not determine a definite relationship between the surgeon's impression of the completeness of tumor removal and length of survival after the second operation, When the KR is at least 60, mean survival time is 26.8 ___ 6.29 weeks. When the KR prior to reoperation is less than 60, mean survival is 11.2 ___ 2.77 weeks. Only one of 13 patients with a KR of less than 60 before reoperation survived longer than 6 months after the second operation.
Four patients lived less than 1 month following reoperation (Table 1) . One patient had a postoperative cerebrospinal fluid leak from the incision site which was further complicated by meningitis and a wound infection. Four other patients developed wound infections. One of these required removal of a bone flap. Another patient's wound dehiscence required reclosure. Based on a change in KR of at least 10, six patients were initially improved by reoperation, five were unchanged, and 13 were worse. Based on a change in KR of at least 20, two patients were improved initially by reoperation, 16 were unchanged, and six were worse.
Discussion
We found no previous report analyzing the factors determining outcome after reoperation for glioblastoma multiforme. Cushing 3 reoperated on 69 of his 183 patients with glioblastoma, but did not report indications for reoperation or duration of survival. Afra, et al., 1 reported that 41 of 265 patients with supratentorial malignant gliomas underwent reoperation. Neither the percentage of patients with glioblastoma nor the results of reoperation for the entire group of 41 patients was reported. 1 Other large reported series of glioblastoma multiforme do contain survival results of reoperated cases. Ray's report 8 of 100 reoperations for various types of benign and malignant brain tumors included only three for glioblastoma multiforme. None of these three patients lived longer than 8 months. Tumor recurrence or death occurred within 4 months in every case. Pool's study 6 of recurrent gliomas included six glioblastomas. The five patients undergoing reoperation on his service had an interoperative interval from 8 to 18 months (median 11 months), and a survival time from 3 to 18 months (median 11 months) after the second operation. Nine of the 506 patients with glioblastoma reported by Roth and Elvidge 9 had two operations. The median interval between operations was 13 months, and median survival time was 15 89 months.
Our data indicate that the functional capacity (KR) is the most significant determinant of survival following a second operation for glioblastoma multiforme. Although interval between operations, when considered alone, is a significant predictor, the significance is lost after adjustment for KR. Other studies have shown a significant relationship between duration of symptoms and survival after a single operation and radiotherapy? ~ Our data confirm this finding for reoperation, but indicate that neurological status (KR) is the more important determinant of outcome. Age, sex, and location of tumor are not significantly related to duration of survival.
Age, interval between operations, and KR accounted for only 28% of the variation in survival after the second operation. Seventy-two percent of the variation is unexplained by our analysis and emphasizes the clinical dilemma of deciding which patients might benefit from another operation. Ransohoff and Lieberman 7 wrote that "reoperation is probably indicated B. Young, et al.
in the occasional patient who is harboring a polar lesion in a relatively silent area and who develops recurrent symptoms of a mass nature, without evidence of active invasion in the surrounding brain, nine months or more after the initial surgery and combined therapies." Similar indications are probably used by many neurosurgeons, but the results of using various criteria for reoperation have not been published.
Our Study provides no firm guidelines for reoperation, but suggests that reoperation is most likely to produce the best result when the KR is at least 60 and the interval between operations is longer than 6 months. Using these criteria, one could expect onethird of the patients with a KR of at least 60 to survive for 6 months. Whether these anticipated results justify a second operation for glioblastoma is a highly individual and difficult decision. No set of variables will reliably predict which particular patients with a KR of at least 60 will survive for 6 months. Our study indicates that reoperation should not be carried out when the KR is less than 60. Only one of the 13 such patients lived for 6 months after reoperation.
